Antisense and Nucleic Acid Drug DevelopmentVol. 7, No. 3 Recruiting the 2-5A System for Antisense TherapeuticsPAUL. F. TORRENCE, WEI XIAO, GUIYING LI, HAGEN CRAMER, MARK R. PLAYER, and ROBERT H. SILVERMANPAUL. F. TORRENCESearch for more papers by this author, WEI XIAOSearch for more papers by this author, GUIYING LISearch for more papers by this author, HAGEN CRAMERSearch for more papers by this author, MARK R. PLAYERSearch for more papers by this author, and ROBERT H. SILVERMANSearch for more papers by this authorPublished Online:30 Jan 2009https://doi.org/10.1089/oli.1.1997.7.203AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited BySmall Molecule Targeted Recruitment of a Nuclease to RNA24 May 2018 | Journal of the American Chemical Society, Vol. 140, No. 22Human Telomerase RNA Degradation by 2'-5'-Linked Oligoadenylate Antisense Chimeras in a Cell-Free System, Cultured Tumor Cells, and Murine Xenograft Models Jayashree M. Paranjape, Da Xu, David M. Kushner, James Okicki, Daniel J. Lindner, Hagen Cramer, Robert H. Silverman, and Douglas W. Leaman15 September 2006 | Oligonucleotides, Vol. 16, No. 3TARGETED THERAPY OF RESPIRATORY SYNCYTIAL VIRUS BY 2-5A ANTISENSE15 November 2011 | Nucleosides, Nucleotides & Nucleic Acids, Vol. 24, No. 5-7Antisense approaches for inhibiting respiratory syncytial virus20 April 2005 | Expert Opinion on Biological Therapy, Vol. 5, No. 2Potent inhibition of respiratory syncytial virus by combination treatment with 2–5A antisense and ribavirinAntiviral Research, Vol. 61, No. 3Probing the activation site of ribonuclease L with new N6-substituted 2′,5′-adenylate trimersBioorganic & Medicinal Chemistry, Vol. 11, No. 9Antiviral Agents, RNA Viruses (Other than HIV), and Orthopoxviruses15 January 2003Antisense TherapyAmerican Journal of Cancer, Vol. 2, No. 4The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus24 June 2016 | Antiviral Chemistry and Chemotherapy, Vol. 13, No. 6Antisense Therapy: Recent Advances and Relevance to Prostate CancerClinical Prostate Cancer, Vol. 1, No. 1Experimental therapy of filovirus infectionsAntiviral Research, Vol. 54, No. 1Targeted Therapy of Respiratory Syncytial Virus in African Green Monkeys by Intranasally Administered 2-5A AntisenseVirology, Vol. 292, No. 1Recent Advances in Stereocontrolled Synthesis of P-Chiral Analogues of Biophosphates21 January 2002Antisense Oligonucleotides in CancerBioDrugs, Vol. 13, No. 3Novel mechanisms for antisense-mediated regulation of gene expressionBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, Vol. 1489, No. 1Triple helix formation and the antigene strategy for sequence-specific control of gene expressionBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, Vol. 1489, No. 1Controlling Gene Expression with 2-5A AntisenseMethods, Vol. 18, No. 32-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selectionAntiviral Research, Vol. 41, No. 3Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and TreatmentClinical Microbiology Reviews, Vol. 12, No. 2Phosphorothioate oligodeoxyribonucleotides inhibit ribonuclease L thereby disabling a mechanism of interferon actionBioorganic & Medicinal Chemistry Letters, Vol. 9, No. 62′,5′-Oligoadenylate-peptide nucleic acids (2–5A-PNAs) activate RNase LBioorganic & Medicinal Chemistry, Vol. 7, No. 3Oxathiaphospholane Method of the Stereocontrolled Synthesis of Phosphorothioate Analogues of OligonucleotidesRespiratory syncytial virus (RSV) disease and prospects for its controlAntiviral Research, Vol. 39, No. 2Selective mRNA degradation by antisense oligonucleotide-2,5A chimeras: Involvement of RNase H and RNase LBiochimie, Vol. 80, No. 8-9Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA21 July 1998 | Proceedings of the National Academy of Sciences, Vol. 95, No. 15Ribonuclease L, a 2-5A-Dependent Enzyme: Purification to Homogeneity and Assays for 2-5A Binding and Catalytic ActivityMethods, Vol. 15, No. 3Targeting RNase L to Human Immunodeficiency Virus RNA with 2-5A-Antisense28 November 2016 | Antiviral Chemistry and Chemotherapy, Vol. 9, No. 3Dissection of the Roles of Adenine Ring Nitrogen (N-1) and Exocyclic Amino (N-6) Moieties in the Interaction of 2-5A with RNase LBiochemical and Biophysical Research Communications, Vol. 245, No. 2Nuclease-Resistant Composite 2‘,5‘-Oligoadenylate−3‘,5‘-Oligonucleotides for the Targeted Destruction of RNA: 2−5A-Iso-antisense3 April 1998 | Journal of Medicinal Chemistry, Vol. 41, No. 9 Volume 7Issue 3Jun 1997 To cite this article:PAUL. F. TORRENCE, WEI XIAO, GUIYING LI, HAGEN CRAMER, MARK R. PLAYER, and ROBERT H. SILVERMAN.Recruiting the 2-5A System for Antisense Therapeutics.Antisense and Nucleic Acid Drug Development.Jun 1997.203-206.http://doi.org/10.1089/oli.1.1997.7.203Published in Volume: 7 Issue 3: January 30, 2009PDF download